BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Recasens M, Aguilera E, Ampurdanés S, Sánchez Tapias JM, Simó O, Casamitjana R, Conget I. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med. 2001;18:764-767. [PMID: 11606177 DOI: 10.1046/j.1464-5491.2001.00562.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017;66:25-32. [PMID: 27761609 DOI: 10.1007/s00262-016-1913-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
3 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
4 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
5 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Nylen ES, Marathe IC, Khan IA, Azevedo R, Hirsch KR. Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C. Am J Med Sci 2008;335:329-30. [PMID: 18414077 DOI: 10.1097/MAJ.0b013e318145a721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Van Der Fits L, Kant M, Van Der Wel LI, Prens EP. Polymorphisms in the Interferon Regulatory Factor-1 Promoter Are Not Associated with Psoriasis and Do Not Influence IFN- α -Induced Th1 Polarization. Journal of Interferon & Cytokine Research 2007;27:841-6. [DOI: 10.1089/jir.2007.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
9 Tosone G, Borgia G, Gentile I, Cerini R, Conte MC, Orlando R, Piazza M. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007;44:167-9. [PMID: 17721757 DOI: 10.1007/s00592-007-0259-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
10 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
11 Tahrani A, Bowler L, Singh P, Coates P. Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C. Eur J Gastroenterol Hepatol. 2006;18:291-293. [PMID: 16462544 DOI: 10.1097/00042737-200603000-00011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
12 Radhakrishnan S, Upadhyay A, Mohan N, Dhar A, Walia HK, Zubaidi G. Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report. Med Princ Pract. 2005;14:281-283. [PMID: 15961942 DOI: 10.1159/000085751] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
13 Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. Diabet Med. 2005;22:340-343. [PMID: 15717885 DOI: 10.1111/j.1464-5491.2005.01412.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kim JD, Sherker AH. Antiviral therapy: role in the management of extrahepatic diseases. Gastroenterology Clinics of North America 2004;33:693-708. [DOI: 10.1016/j.gtc.2004.04.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
15 van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004;122:51-60. [PMID: 14962089 DOI: 10.1046/j.0022-202X.2003.22113.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 4.7] [Reference Citation Analysis]
16 Primo Vera J. Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c. Gastroenterología y Hepatología 2004;27:69. [DOI: 10.1016/s0210-5705(03)79089-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58. [PMID: 12969081 DOI: 10.1046/j.1365-2036.2003.01681.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
18 Jabr FI, Ordinario MMD. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. The American Journal of Medicine 2003;115:158-9. [DOI: 10.1016/s0002-9343(03)00301-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
19 Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226-S236. [PMID: 12407598 DOI: 10.1002/hep.1840360729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
20 Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:S226-36. [PMID: 12407598 DOI: 10.1053/jhep.2002.36991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 0.5] [Reference Citation Analysis]